You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,926,975

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,926,975

Title:	Method of treating ankylosing spondylitis
Abstract:	The invention provides methods, uses and compositions for the treatment of ankylosing spondylitis (AS). The invention describes methods and uses for treating ankylosing spondylitis, wherein a TNF.alpha. inhibitor, such as a human TNF.alpha. antibody, or antigen-binding portion thereof, is used to reduce signs and symptoms of ankylosing spondylitis in a subject. Also described are methods for determining the efficacy of a TNF.alpha. inhibitor for treatment of ankylosing spondylitis in a subject.
Inventor(s):	Wong; Robert L. (Basking Ridge, NJ), Kupper; Hartmut (Mutterstadt, DE), Medich; John R. (Highland Park, IL)
Assignee:	AbbVie Biotechnology Ltd (Hamilton, BM)
Application Number:	14/306,658
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,926,975
Patent Claims:	1. A method of treating active ankylosing spondylitis (AS) in a subject having total spinal ankylosis comprising selecting a subject having active AS and total spinal ankylosis, and subcutaneously administering 40 mg of an isolated human anti-TNF.alpha. antibody to the subject once every other week, wherein the human anti-TNF.alpha. antibody comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 2. The method of claim 1, wherein the human anti-TNF.alpha. antibody is adalimumab. 3. The method of claim 1, wherein the subject had an inadequate response to treatment with at least one NSAID. 4. A method of reducing signs and symptoms of ankylosing spondylitis (AS) in a subject having active AS and total spinal ankylosis, the method comprising selecting a subject having active AS and total spinal ankylosis and subcutaneously administering 40 mg of an isolated human anti-TNF.alpha. antibody to the subject once every other week, wherein the human anti-TNF.alpha. antibody comprises a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2. 5. The method of claim 4, wherein the human anti-TNF.alpha. antibody is adalimumab. 6. The method of claim 4, wherein the subject had an inadequate response to treatment with at least one NSAID.

Details for Patent 8,926,975

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002	⤷ Try a Trial	2026-06-08
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008	⤷ Try a Trial	2026-06-08
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013	⤷ Try a Trial	2026-06-08
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014	⤷ Try a Trial	2026-06-08
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015	⤷ Try a Trial	2026-06-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.